Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Euthymics Bioscience Inc.

euthymics.com

Latest From Euthymics Bioscience Inc.

Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round

Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.

Financing Coronavirus COVID-19

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Deals M & A

Start-Up Previews (03/2011)

A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Antidepressants: Emerging From Their Funk?," includes profiles of Euthymics Bioscience, Naurex and PharmaNeuroBoost. Plus these Start-Ups Across Health Care: Edge Therapeutics, Ensemble Therapeutics, Magnetecs, Mederi Therapeutics and Surefire Medical.

Antidepressants: Emerging From Their Funk?

Forest’s acquisition of Clinical Data to get its just-approved antidepressant signals continuing strong demand. But better, and much needed, treatments remain elusive. We profile four emerging antidepressant drug developers in this issue: Euthymics Biosciences, Naurex and PharmaNeuroBoost.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Euthymics Bioscience Inc.
  • Senior Management
  • Anthony A McKinney, Pres. & CEO
    Thomas A Shea, CFO
    Franklin P Bymaster, CSO
    Pierre Tran, MD, CMO
  • Contact Info
  • Euthymics Bioscience Inc.
    Phone: (617) 758-0300
    43 Thordike St.
    Ste S1-3
    Cambridge, MA 02141
    USA
UsernamePublicRestriction

Register